Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Debio 1143 and High-Dose Cisplatin Chemoradiotherapy in High-Risk Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Double-Blind, Multicentre, Randomised, Phase 2 Study
This publication was sponsored by Debiopharm International SA.
This Clinical Brief explores the double-blind, multicentre, randomised phase 2 study (NCT02022098) of Debio 1143 and high-dose cisplatin chemoradiotherapy in patients with high-risk locoregionally advanced squamous cell carcinoma of the head and neck.
